A small sample of body fluids is sufficient as a basis for analysis
Reliable prognosis for risk in the symptom-free state
More than 10 years head start for prevention and therapy
Our protein detection, using the example of Alzheimer’s
What starts with a simple body fluid test culminates in the ability to detect various neurodegenerative diseases before symptoms appear, thanks to the betaSENSE technology. The procedure explained step by step using the example of Alzheimer’s disease.
So-called amyloid-beta (Aβ) deposits, also known as plaques, are typical of Alzheimer’s disease. The Aβ
protein is overproduced by the body. It accumulates and consequently changes its structure. This leads to
misfolding and thence to clumping. With the help of special antibodies, the Aβ proteins are filtered out of
body fluids to examine their nature.
Infrared beams measure the structure of the extracted Aβ-proteins. Misfolded proteins absorb the rays differently. The patented platform of the immuno-infrared sensor ensures that no non-specific proteins bind during measurement, so that the reflection result is not falsified.
Other degenerative diseases of the central nervous system, such as Parkinson’s disease or ALS (amyotrophic lateral sclerosis), can also be identified first by misfolding of certain marker proteins. In order to detect them, the antibodies on the sensor platform are changed accordingly to filter out relevant proteins from body fluids here as well.
The fields of application of betaSENSE technology.
The betaSENSE method based on a new platform technology combines the insights from years of cutting-edge research in the field of protein science. In clinical application, it offers new perspectives to researchers and facilitates the path to drug development.
In order to be able to discover new active substances and develop drugs, pharmaceutical research needs suitable methods and technologies. The betaSENSE platform technology offers researchers a precise method for measuring pharmaceutical mechanisms of
Identifying high-risk persons for studies
With betaSENSE protein
testing, the baseline criteria for participants in clinical trials can be reliably checked. The differentiated risk rating provides valuable information for changes to the participant setup that may be necessary.
Validation of study-related diagnostics
For study-related analytics, specialised laboratories gain new validation options with the betaSENSE protein based testing. We also runs our own laboratories and a reference laboratory for
Aktuelle klinische Studien mit betaSENSE-Technologie.
Wir stellen eine Plattformtechnologie zur Verfügung, damit neue Medikamente zur Behandlung neurodegenerativer Erkrankungen entwickelt werden können. Eine neue Ära der Proteindiagnostik.
Early diagnosis increases quality of life.
Starting drug therapy in time.
Neurodegenerative diseases damage the brain irreparably if their progression is not stopped in time. Pharmaceutical companies are therefore working on the development of drugs to influence progression of the disease. For these drugs to work, diagnosis in due time is necessary – before irreparable damage to the brain has occurred. At betaSENSE we work on enabling such early diagnosis. The innovative betaSENSE technology will mean a breakthrough for successful pharmacological treatment of dementia patients as well as people with other neurodegenerative diseases.
Adjusting the lifestyle delays the progression of the disease.
Studies show that a balanced diet, regular exercise, cognitive challenges, stress reduction and abstention from alcohol and recreative drugs can significantly slow down the progression of neurodegenerative diseases. Early diagnosis therefore helps affected persons to adjust their lifestyle accordingly.